Consolidation in High-Tech Health Care: Lessons from Other Industries
The journey to profitability in high-tech was always easy to define but difficult to execute: invest heavily in R&D, produce innovative technology and cement strong relationships. But as payers demand value for their dollars, high-tech companies need to reposition products in their portfolio for the consolidation that has just begun.
You may also be interested in...
American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.
A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.